Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02VVS
|
||||
| Former ID |
DAP000113
|
||||
| Drug Name |
Filgrastim
|
||||
| Synonyms |
Neupogen (TN); Religrast (TN); Nugraf. (TN)
|
||||
| Therapeutic Class |
Immunomodulatory Agents
|
||||
| Company |
Amgen Inc
|
||||
| Formula |
C845H1343N223O243S9
|
||||
| CAS Number |
CAS 143011-72-7
|
||||
| SuperDrug ATC ID |
L03AA02
|
||||
| Target and Pathway | |||||
| Target(s) | Macrophage colony-stimulating factor receptor | Target Info | Binder | [535943], [537204] | |
| NetPath Pathway | Leptin Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| References | |||||
| Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| Ref 542000 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6968). | ||||
| Ref 535943 | Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8. | ||||
| Ref 537204 | XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma. 2009 Mar;50(3):374-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.